BRIEF-Gilead's Odefsey meets primary objective in phase 3B studies By: Reuters: Company News July 21, 2016 at 16:45 PM EDT * Odefsey (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) Meets Primary 48-Week objective in two phase 3B studies Read More >> Related Stocks: Gilead Sciences